ECTRIMS
EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS

Detail of Pharmaceutical Funding Sources (01.01.2025 – 31.12.2025)

Income indicated below relates to: Congress Exhibition, Programme Advertisements, Sponsored Symposia, and General Onsite Sponsoring; Society initiatives sponsoring

Industry-related Income in 2025: Breakdown

Contributing companies in 2025	Total contribution in 2025	% of Total income in 2025
Alexion, AstraZeneca Rare Disease	€ 370'200.00	3.84%
Amgen	€ 196'700.00	2.04%
Bristol Myers Squibb	€ 320'260.00	3.32%
Celestra Health Systems	€ 3'510.00	0.04%
Coloplast	€ 16'030.00	0.17%
Fujirebio Europe	€ 10'530.00	0.11%
Immunic AG	€ 14'040.00	0.15%
Juvisé Pharmaceuticals	€ 162'160.00	1.68%
machineMD AG	€ 3'510.00	0.04%
Merck Healthcare KGaA	€ 466'200.00	4.84%
Merz Therepeutics GmbH	€ 5'265.00	0.05%
Novartis Pharma AG	€ 473'200.00	4.91%
Ottobock	€ 7'020.00	0.07%
Peer Voice	€ 88'000.00	0.91%
Quanterix	€ 3'510.00	0.04%
Roche	€ 502'650.00	5.22%
Sandoz	€ 76'500.00	0.79%
Sanofi	€ 643'300.00	6.68%
TG Therapeutics & Neuraxpharm	€ 247'300.00	2.57%
UCB	€ 146'440.00	1.52%
Wieslab Diagnostic Service	€ 3'510.00	0.04%
Total Industry Income in 2025	**€ 3'759'835.00**	